CD40LG and Thromboembolism: Kim et al. (2017) found that a novel anti-human CD40L (CD154) domain Ab (dAb) that prolonged rhesus renal allograft survival without thromboembolism, and that synergized with conventional IS to more markedly control graft rejection, increased CD4+CD25+Foxp3+ Treg frequency.